Has erdafitinib been officially launched in China? What are the purchasing channels?

Erdafitinib has been officially launched in China, but it has not yet been included in medical insurance. Since the drug has been on the market for a short period of time, relevant policies and price information may still be in the adjustment stage. Therefore, patients may face certain difficulties when purchasing the drug domestically. Nonetheless, as the market gradually opens up, more pharmacies and hospitals may gradually provide the drug, but patients still need to consult their local medical institutions or pharmacies for detailed purchase channels.

Since erdafitinib is not currently covered by medical insurance and its price is relatively high, domestic patients often encounter financial burden issues when purchasing the drug. The drug is relatively expensive in China, generally costing tens of thousands of yuan, so many patients may choose to purchase it through overseas channels to reduce financial pressure. The original drug of erdafitinib in foreign markets is mainly provided by pharmacies in Hong Kong, China, and the price is as high as more than 20,000 yuan. When purchasing, it needs to be purchased through Hong Kong pharmacies or related international pharmaceutical agents.

In addition to original drugs, patients can also choose to purchase overseas generic drugs. Compared with original drugs, the price of generic drugs is relatively cheaper, usually ranging from a few hundred yuan to more than 2,000 yuan, and their drug ingredients are basically the same as the original drugs. Generic drugs from countries such as Laos and Bangladesh are common. The quality of these drugs has been certified by international drug regulatory agencies and can provide patients with more economical options. Through these overseas channels, patients can effectively reduce treatment costs.

Generally speaking, although erdafitinib has been launched in China, patients still have to rely on channels in the international market to purchase it because it is not included in medical insurance and the price is high. With the gradual adjustment of domestic medical insurance policies and prices, the purchasing channels and burdens of domestic patients may improve in the future. Patients should choose the appropriate purchasing channel under the guidance of a doctor based on their own condition and financial situation.

Reference link:https://www.balversa.com/